医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

JXTGE Announces Sale of Irvine Scientific to FujiFilm

2018年03月30日 AM12:02
このエントリーをはてなブックマークに追加


 

SANTA ANA, Calif.

JXTG Nippon Oil & Energy Corporation has announced it has agreed to sell Irvine Scientific Sales Company, Inc. and IS Japan Co., Ltd. to FUJIFILM Corporation (FujiFilm).

JXTG Energy acquired Irvine Scientific in 1987 and launched IS Japan in 1989; both companies have continuously expanded to become significant suppliers of cell culture media and products to the biopharmaceutical, cell therapy and medical markets in their respective regions. Although the business has experienced significant growth, life sciences and medical devices are not synergistic for JXTG Energy’s core business going forward.

JXTG Energy determined it would be best for the Irvine Scientific group to continue under ownership which is synergistic to Irvine Scientific products and services.

FujiFilm announced it would acquire the Irvine Scientific group and maximize their synergy in its significant and growing bio-medical businesses. FujiFilm expects increased demand and needs of biopharmaceutical products and regenerative medicine therapy is driving current rapid growth of the cell culture media market and estimates continued strong growth in the coming years.

Irvine Scientific is an innovator of cell culture media, to biopharmaceutical, assisted reproductive technology, and regenerative medicine customers. By applying its high capabilities in R&D and Quality systems, coupled with long experience, Irvine Scientific has developed a strong presence serving customer needs. Irvine Scientific’s California, USA and Saitama, Japan cGMP facilities will be transferred and provides capacity to supply high-quality products in a timely manner worldwide.

FujiFilm is advancing growth strategies within healthcare space, investing in biopharmaceutical contract development/manufacturing, and regenerative medicine. Prior to this announcement, FujiFilm acquired the global leader in iPS cell technologies, Cellular Dynamics International, Inc (“CDI”) and has entered into cell culture media space with the acquisition of general reagents manufacturer, Wako Pure Chemical Industries, Ltd. (“Wako Pure Chemical”). With the acquisition of Irvine Scientific, FujiFilm will have a full product line supporting customers supplying antibody drugs to assisted reproductive technologies and cell therapy, and will also enable FujiFilm to strengthen its overseas business. FujiFilm announced it plans to further accelerate competitive media development and expand cell culture media business by applying chemical synthesis and design technologies acquired through its original business in photographic films and from Japan Tissue Engineering (“J-TEC”), as well as cell growth and manufacturing technologies from CDI and FUJIFILM Diosynth Biotechnologies.

In addition, FujiFilm plans on maximizing synergies outside of cell culture business, combining media technologies and products of Irvine Scientific with FujiFilm Group’s biomedical technologies and products. Specific synergies mentioned include (1) expansion of contract development/manufacturing of biomedicine (2) acceleration of research and development in regenerative medicine (3) expansion of research-purpose chemical reagents business.

The Irvine Scientific Group is excited about this change and anticipates continued acceleration of its cell culture media businesses under new ownership.

ENDS

About Irvine Scientific
Irvine Scientific, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 45 years, Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

For more information visit http://www.irvinesci.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180329005777/en/

CONTACT

Irvine Scientific
Lori Serles
Phone: 949-261-7800 x145
Email:
lserles@irvinesci.com
or
Zyme
Communications

Lorna Cuddon
Phone: +44 (0)7811996942
Email:
lorna.cuddon@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法